Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon, A Target Itself, To Acquire Remainder Of ChemGenex

This article was originally published in The Pink Sheet Daily

Executive Summary

Just a week after purchasing oncology company Gemin X, Cephalon is buying the remaining shares of Australian biotech ChemGenex that it does not already own for $163 million.

You may also be interested in...



Teva’s Synribo Clears FDA For Third-Line Chronic Myeloid Leukemia

Omacetaxine, which was originally submitted by ChemGenex as Omapro, demonstrated response rates of 14% to 18% in patients who had failed two or more tyrosine kinase inhibitors. It enters a crowded space that is likely to add a new member, Ariad’s ponatinib, in the coming months.

ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA

DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.

ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA

DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.

Topics

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel